Citius pharmaceuticals announces fda acceptance of ind application for its phase 2b study of halo-lido for the prescription treatment of hemorrhoids

Cranford, n.j., feb. 15, 2022 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that the u.s. food and drug administration (fda) has issued a study may proceed letter for halo-lido for the treatment of hemorrhoids.
CTXR Ratings Summary
CTXR Quant Ranking